Table 2 Medications ever used to treat sJIA/AOSD
Medications ever used | Unvaccinated sJIA (n = 50) | Vaccinated sJIA (n = 81) | Unvaccinated sJIA + AOSD (n = 51) | Vaccinated sJIA + AOSD (n = 99) | |
|---|---|---|---|---|---|
NSAIDS | 38 (76%) | 71 (88%) | 39 (76%) | 83 (84%) | |
Steroids | |||||
Oral | 45 (90%) | 70 (86%) | 46 (90%) | 88 (89%) | |
IV | 35 (70%) | 52 (64%) | 35 (68%) | 58 (59%) | |
IL-1 inhibitors | |||||
Anakinra | 41 (82%) | 62 (76%) | 41 (80%) | 71 (72%) | |
Canakinumab | 29 (58%) | 50 (62%) | 29 (56%) | 51 (52%) | |
Rilonacept | 2 (4%) | 0 (0%) | 2 (3%) | 0 (0%) | |
Tocilizumab | 33 (66%) | 41 (51%) | 33 (64%) | 46 (46%) | |
Methotrexate | 22 (44%) | 36 (71%) | 23 (45%) | 45 (45%) | |
JAK inhibitors | |||||
Baricitinib | 0 (0%) | 2 (2%) | 0 (0%) | 2 (2%) | |
Tofacitinib | 20 (40%) | 16 (20%) | 20 (39%) | 17 (17%) | |
Other JAKi | 12 (24%) | 7 (9%) | 12 (23%) | 8 (8%) | |
Cyclosporin | 14 (28%) | 25 (31%) | 14 (27%) | 26 (26%) | |
Tacrolimus | 13 (26%) | 10 (12%) | 13 (25%) | 11 (11%) | |
Abatacept | 6 (12%) | 7 (9%) | 6 (11%) | 9 (9%) | |
TNF inhibitors | |||||
Adalimumab | 5 (10%) | 6 (7%) | 5 (10%) | 9 (9%) | |
Etanercept | 5 (10%) | 2 (2%) | 5 (10%) | 3 (3%) | |
Infliximab | 3 (6%) | 3 (4%) | 3 (6%) | 4 (4%) | |
Emapalumab | 10 (20%) | 2 (2%) | 10 (20%) | 2 (2%) | |
Cyclophosphamide | 2 (4%) | 3 (4%) | 2 (4%) | 3 (3%) | |
Azathioprine | 0 (0%) | 1 (1%) | 0 (0%) | 2 (2%) | |
Bone marrow transplant | 1 (2%) | 1 (1%) | 1 (2%) | 1 (1%) | |
IL-18 inhibitor | 0 (0%) | 1 (1%) | 0 (0%) | 1 (1%) | |
Hydroxychloroquine | 1 (2%) | 2 (2%) | 1 (2%) | 4 (4%) | |
Thalidomide/lenalidomide | 0 (0%) | 2 (2%) | 0 (0%) | 2 (2%) | |
Leflunomide | 0 (0%) | 4 (5%) | 0 (0%) | 4 (4%) |